Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

237.51 10.19 +4.48%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2024: revenue by regions, and margins
U.S.	3,660	89.95%
Europe	313	7.69%
All other	96	2.36%
Gross margin		89.05%
Operating margin		17.61%
Pre-tax margin		11.56%

Revenue by product or service $m

Line	FY2017	FY2016
Xyrem	1,187 73.31%	1,108 74.44%
Erwinaze And Erwinase	197 12.19%	201 13.49%
Defitelio/defibrotide	134 8.26%	109 7.32%
Other	50 3.08%	31 2.08%
Vyxeos	34 2.09%	0 0.00%
Product And Services, Royalties And Contract Revenue	17 1.07%	11 0.72%
Sunosi	0 0.00%	—
Prialt	—	29 1.96%
Product sales, net	1,601	1,477
Revenue	1,619	1,488

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
U.S.	3,832 89.78%	3,660 89.95%	3,490 91.02%	3,370 92.10%	2,820 91.14%	2,145 90.73%	1,964 90.86%	1,728 91.36%	1,463 90.41%	1,356 91.13%	1,193 90.04%	1,007 85.89%	793 90.84%	538 91.85%	266 97.59%	169 97.43%	114 88.81%
Europe	341 7.99%	313 7.69%	269 7.02%	240 6.55%	230 7.44%	175 7.41%	150 6.95%	126 6.66%	126 7.76%	108 7.28%	104 7.82%	127 10.80%	62 7.09%	39 6.59%	6 2.29%	4 2.40%	14 10.91%
All other	95 2.22%	96 2.36%	75 1.96%	49 1.35%	44 1.42%	44 1.85%	47 2.19%	37 1.98%	30 1.83%	24 1.60%	28 2.14%	39 3.31%	18 2.07%	9 1.56%	0 0.12%	0 0.17%	0 0.28%
Revenue	4,268	4,069	3,834	3,659	3,094	2,364	2,162	1,891	1,619	1,488	1,325	1,173	872	586	272	174	128

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Active Xywav patients	Q3 FY2026	17.6K	15.7K	+11.96%
Xywav idiopathic hypersomnia patients	Q3 FY2026	6.2K	5.0K	+24.75%
Xywav narcolepsy patients	Q3 FY2026	11.4K	10.7K	+6.06%
Xywav net patient additions	Q3 FY2026	425.00	450.00	−5.56%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024
Active Xywav patients	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Xywav idiopathic hypersomnia patients	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Xywav narcolepsy patients	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Xywav net patient additions	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.